SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

What makes MOG an absolute game-changer is our relentless dedication to memes and viral brilliance! We don't settle for mediocrity; we plunge into the realm of sheer awesomeness! Our community is a powerhouse of meme warriors, unleashing an unstoppable onslaught of viral memes that'll leave you in awe and stitches!  We're not here to play games; we're here to dominate! MOG is all about pushing the boundaries, smashing through barriers, and leaving our competitors eating our dust! Our passion for humor burns like an inferno, and we won't rest until the entire internet bows down to our meme supremacy!  And our community? It's a brotherhood, an unyielding powerhouse of support and camaraderie! When you're part of MOG, you're part of an unstoppable force, a family forged by the fire of meme revolution!  So, if you're ready to be part of the most intense, mind-bending memecoin movement ever conceived, then buckle up, strap in, and brace yourself! MOG is here to claim the throne, and we're taking no prisoners! Get ready to witness meme history in the making!

 MOG Coin

MOG Coin is trending amidst community excitement about potential gains, with some suggesting it could mirror past rallies. Bullish investors are actively buying and holding, while others debate whether it's a "scam" or a promising meme coin. Some traders are also pointing to a potential Robinhood listing on the horizon.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

VELO is trending amid discussions of its strategic partnerships, particularly within the defense and aerospace sectors, with community members highlighting potential growth catalysts. The company's collaborations with iRocket and its focus on U.S.-based manufacturing are sparking interest. Discussions also include the company's financial health, potential for profitability, and technical analysis of the stock.

AABG Token

AABBG is trending as investors discuss its potential, production updates, and recurring dividends, while others express concerns about timelines and dilution. Community members debate market manipulation and the company's execution, with some calling for patience and others demanding more transparency. Sentiment is mixed as shareholders await updates on financials, buybacks, and the AABB wallet.

Protagonist Therapeutics, Inc. a clinical-stage biopharmaceutical company, which engages in discovering and developing peptide-based therapeutic drugs to address unmet medical needs. Its product pipeline includes PTG-300, PTG-200, and PN-943. The company was founded by Mark L. Smythe on August 22, 2006 and is headquartered in Newark, CA.

Protagonist Therapeutics Inc

Protagonist Therapeutics ( $PTGX ) is trending due to positive Phase 2b trial results of Icotrokinra in ulcerative colitis, fueling speculation of a potential buyout by Johnson & Johnson ( $JNJ ). The community is actively discussing potential deal prices and the strategic fit for $JNJ , while analysts are raising price targets. Some traders are wary of overvaluation and potential pullbacks following the surge.

Internet Computer (IC) is the world’s first blockchain that is capable of running at web speed at unrestrictive capacities. Built by the DFINITY Foundation, IC aims to recreate the web by supporting smart contract development at scale and changing the way people can interact using web services. Internet Computer aims to extend the public internet, so that it can be the world’s computing platform, in a decentralized manner. Internet Computer sets to revolutionalize the design of the crypto economy, with an aim to overhaul traditional software services.   The project was founded in October 2016 by Dominic WIllams and have raised a total of $121 million from investors such as Adreessen Horowitz, Polychain Capital, Multicoin Capital and such. On May 10, 2021, DFINITY launched the Internet Computer into the public domain, marking it a major milestone for ICP as it means the internet now functions as a decentralised global computer. This is marked by the release of all of the Internet Computer’s source code into the public domain, as well as ICP utility token that allows tens of thousands of community members to govern the Internet Computer network.  ICP is Internet Computer's native token. It plays three prominent roles:  1. Network Governance: Users that participate in the governance will be rewarded with ICPI 2. Production of Cycles for Compute: ICP can be converted into cycles where it is used as the transaction fee to access the network. Cycles are burned after used. 3. Rewarding Users: ICP is used as the rewards to incentivize users to participate in the network such as securing the network.

Internet Computer

Internet Computer (ICP) is trending as the community discusses its potential to decentralize the internet and challenge cloud providers, drawing comparisons to Bitcoin's impact on traditional finance.  The launch of Caffeine AI is a key catalyst, though some express concerns over adoption and price movement, while others point to growing network usage and Bitcoin integration as bullish signals. Community debates include its long-term potential, criticisms of its tokenomics, and whether it can achieve mainstream adoption.

This first memecoin ever created completely by AI.

Turbo Toad Token

Turbo Toad Token ($TURBO) is gaining attention as traders discuss its potential for a significant breakout, drawing comparisons to previous meme coin surges. Community members express bullish sentiment, citing technical indicators and anticipating a move towards new all-time highs. Discussions also revolve around possible exchange listings and the broader altcoin season, with some highlighting $TURBO's strong community and unique AI-generated aspect.

BlackRock Institutional Trust Company N.A. - iShares China Large-Cap ETF

iShares China Large-Cap ETF

The iShares China Large-Cap ETF ($FXI) is trending amid U.S.-China trade tensions and speculation around potential tariff adjustments, influencing investor sentiment. Community discussions revolve around the ETF's technical uptrend, potential resistance levels, and the broader implications of trade dynamics on Chinese equities. Some investors express bullish sentiment, citing discounted valuations, while others remain cautious due to geopolitical risks and the potential for renewed trade conflicts.

Berkshire Hathaway, Inc. is a holding company, which engages in the provision of property and casualty insurance and reinsurance, utilities and energy, freight rail transportation, finance, manufacturing, and retailing services. It operates through the following segments: Insurance, Burlington Northern Santa Fe, LLC (BNSF), Berkshire Hathaway Energy (BHE), Pilot Travel Centers (PTC), Manufacturing, McLane, and Service and Retailing. The Insurance segment includes the underwriting of GEICO, Berkshire Hathaway Primary Group, and Berkshire Hathaway Reinsurance Group. The BNSF segment involves the operation of railroad systems. The BHE segment focuses on regulated electric and gas utility, power generation and distribution, and real estate brokerage activities. The PTC segment consists of managing travel centers and marketing of wholesale fuel. The Manufacturing segment refers to industrial, consumer and building products, home building, and related financial services. The McLane segment covers the wholesale distribution of groceries and non-food items. The Service and Retailing segment relates to the provision of shared aircraft ownership programs, aviation pilot training, electronic components distribution, retailing businesses, automobile dealerships and trailer, and furniture leasing services. The company was founded by Oliver Chace in 1839 and is headquartered in Omaha, NE.

Berkshire Hathaway Inc. - Ordinary Shares - Class A

Berkshire Hathaway is trending amid news of Warren Buffett stepping down as CEO by year-end, with Greg Abel expected to take over, though Buffett will remain chairman. Community discussions revolve around the company's future direction, Q1 earnings, massive cash reserves, and if the stock will maintain its premium valuation without Buffett at the helm. There's also focus on Buffett's recent comments on tariffs and their potential impact on Berkshire's diverse businesses.

NextDecade Corp. is a development company, which focuses on liquefied natural gas (LNG) export projects and associated pipelines. It develops and manages land-based and floating liquefied natural gas projects in the Gulf Coast with focus on the Rio Grande LNG. The company was founded by Kathleen Eishbrenner in 2010 and is headquartered in Houston, TX.

NextDecade Corporation

NextDecade ($NEXT) is trending amid discussions around long-term price forecasts based on LNG prices and project milestones, with some community members projecting significant upside potential as trains come online; the stock is also garnering attention due to insider buying, positive news regarding its Rio Grande LNG project expansion, and speculation about potential catalysts. Community members are weighing the potential for $NEXT to become a major player in the LNG market, comparing it to Cheniere, while also discussing concerns around debt and potential delays.

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to global pharmaceutical companies. Its portfolio includes royalties, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. The company was founded by Pablo Gerardo Legorreta and Rory B. Riggs in 1996 and is headquartered in New York, NY.

Royalty Pharma plc - Ordinary Shares - Class A

Royalty Pharma (RPRX) is trending amid discussions about its unique business model and recent activity, including news of a collaboration with Merck and an expanded leadership team. Community members are debating the stock's potential and fair valuation, with some expressing frustration over its price action despite positive analyst ratings. Insider selling continues to be a key concern for some investors.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) today announced that five posters will be presented in collaboration with independent investigators highlighting new data on LUPKYNIS (voclosporin) at the...

Aurinia Pharmaceuticals on Monday pushed back on criticism of its lupus drug Lupkynis (voclosporin) by a top FDA official who had raised questions about the medicine’s clinical benefit in a LinkedIn post that has since been deleted.Shares of Aurinia tumbled 16% to $11.06, marking their worst day since February 2024, before recovering 4% in after-hours trading to $11.51.In a statement, Aurinia reiterated its positive outlook for Lupkynis, stating that it has an established benefit–risk profile. Aurinia highlighted that the drug was granted full FDA approval in January 2021 following the AURORA 1 study, and received additional approval in April 2024 based on data from the AURORA 2 study, which demonstrated its efficacy and safety over a three-year period.The selloff followed a post by George Tidmarsh, director of the FDA’s drug center, who said Lupkynis “has not been shown to provide a direct clinical benefit for patients.” His comments were part of a broader discussion about the agency’s use of surrogate endpoints, which are biological measures used to accelerate drug approvals, that he said had led to both “notable successes and failures.”The post drew widespread attention not only for its criticism of a specific drug and company, something regulators almost never do publicly, but also for its choice of platform.&nbsp;Soon after media reports surfaced, Tidmarsh deleted the post and clarified that his comments were “personal views” that “do not reflect those of the FDA or HHS,”&nbsp; adding that all official communications would continue to be made through formal agency channels.On Stocktwits, retail sentiment for Aurinia was ‘extremely bullish’ amid a&nbsp;whopping 10,040% surge in 24-hour message volume.One user said the stock’s decline wasn’t surprising, describing it as a healthy pullback after a strong run that could set up the next move higher.<stembedurl>https://stocktwits.com/Itsagame999/message/630423873</stembedurl>Other users expressed frustration with the company’s response, saying they had expected a stronger reaction and were disappointed by what they described as a brief, generic statement, with one adding they had lost $70,000 on the drop.<stembedurl>https://stocktwits.com/timfris/message/630421172</stembedurl><stembedurl>https://stocktwits.com/Dallas9/message/630420635</stembedurl><a href="https://stocktwits.com/symbol/AUPH">Aurinia’s stock</a> has risen 23.2% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Aurinia’s stock (AUPH) has risen 23.2% so far in 2025. (Photo credit: Getty Images)

Aurinia Pharma Stands By Lupus Drug After FDA Official’s Retracted Post Sparks 16% Selloff — Retail Stays Bullish On Recovery

The company reiterated its confidence in Lupkynis’ long-term efficacy and safety following its approval and the submission of supplementary data.

Equity

Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know

Aurinia (AUPH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Aurinia Pharmaceuticals (AUPH) Q2 Earnings Miss Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of -5.88% and +10.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Implied Volatility Surging for Aurinia Pharmaceuticals Stock Options

Investors need to pay close attention to AUPH stock based on the movements in the options market lately.

Retail chatter around Aurinia Pharmaceuticals picked up pace late Sunday, with investors eyeing an update on the company’s early-stage AUR200 trial targeting autoimmune conditions later in the day.The experimental therapy, first dosed in healthy volunteers in September 2024, is being evaluated in a single ascending dose study.&nbsp;The program is assessing safety, tolerability, drug behavior in the body, and biomarker response.&nbsp;AUR200 works by targeting both BAFF (B-cell Activating Factor) and APRIL (A Proliferation-Inducing Ligand), proteins involved in immune system regulation.&nbsp;The company has said it plans to pursue one broader indication and one rare disease, both with relatively few existing treatments.&nbsp;Funding for development is coming from Aurinia’s current cash flow.In May,&nbsp;<a href="https://stocktwits.com/symbol/AUPH">Aurinia</a> reported new findings from its Phase 3 AURORA 1 study of Lupkynis (voclosporin), its approved treatment for lupus nephritis.&nbsp;The post-hoc analysis suggested&nbsp;that patients receiving triple therapy with Lupkynis, mycophenolate mofetil (MMF), and low-dose steroids achieved better proteinuria outcomes than those on MMF and steroids alone.&nbsp;&nbsp;Adverse event rates were comparable between groups.On Stocktwits, retail sentiment for <a href="https://stocktwits.com/symbol/AUPH">Aurinia Pharmaceuticals</a> was ‘extremely bullish’ amid ‘extremely high’ message volume.One user said they wouldn’t be selling even if the stock hit $10, saying they were “in it for the big bucks.”&nbsp;<stembedurl>https://stocktwits.com/RedBarnCannabis/message/619401660</stembedurl>Another pointed out that historically, strong data has moved the stock significantly and stated that with Aurinia’s sizable cash reserves, dilution concerns were minimal, adding that they were hoping for double-digit gains following the update.<stembedurl>https://stocktwits.com/timfris/message/619390483</stembedurl>The stock has declined 1.5% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Retail Bulls Charge Into Aurinia Pharmaceuticals Ahead Of Autoimmune Trial Results

AUR200 targets both BAFF and APRIL, which are key immune system proteins. It is being developed for one large indication and one rare disease.

Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains?

Aurinia (AUPH) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Is the Options Market Predicting a Spike in Aurinia Pharmaceuticals (AUPH) Stock?

Company News for May 13, 2025

Shares of Aurinia Pharmaceuticals Inc. (AUPH) surged 3% in premarket trading on Monday after the company’s first-quarter (Q1) earnings topped Wall Street expectations.The biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20250512965572/en/Aurinia-Pharmaceuticals-Reports-Financial-Results-for-the-Three-Months-Ended-March-31-2025">reported</a> a 24% year-on-year (YoY) jump in its first-quarter (Q1) total revenue to $62.5 million, surpassing an analyst estimate of $61.06 million, according to Finchat data.The surge in revenue was primarily driven by a 25% YoY jump in net product sales of Lupkynis, the company’s FDA-approved oral therapy for treating adult patients with active lupus nephritis, to $60 million.For the three months ending March 31, 2025, the company reported a net income of $23.3 million, compared to a loss of $10.7 million in 2024.Diluted earnings per share came in at $0.16 for the quarter, compared to a loss of $0.07 per share recorded in the corresponding period of 2024, and above an analyst estimate of $0.1. &nbsp;&nbsp;&nbsp;&nbsp;Aurinia ended the quarter with cash, cash equivalents, restricted cash, and investments of $312.9 million, compared to $358.5 million on Dec. 31, 2024.CEO Peter Greenleaf said the company looks forward to a “strong performance” in 2025.The firm also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.On Stocktwits, retail sentiment around Aurinia jumped from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume stayed at ‘normal’ levels.<figure class="image"><img style="aspect-ratio:632/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_12_at_7_28_54_AM_png_b95ef3aeed.webp" alt="AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits" width="632" height="60"><figcaption>AUPH's Sentiment Meter and Message Volume as of 7:30 a.m. ET on May 12, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/AUPH">AUPH stock</a> is down by about 9% this year but up by over 59% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/expedia-retail-traders-remain-optimistic-despite-q1-revenue-miss/chiNeqjRbme">Expedia Retail Traders Remain Optimistic Despite Q1 Revenue Miss Ahead Of Holiday Travel Season</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

Aurinia Stock Rallies On Upbeat Q1 Earnings, CEO Expects Strong Performance in 2025: Retail Sentiment Brightens

The company also reiterated its full-year total revenue guidance of $250 million to $260 million and net product sales guidance of $240 million to $250 million.

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada.

Aurinia Pharmaceuticals Inc

Will Palantir ($PLTR) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

Palantir Technologies Inc

) beat quarterly earnings? 
 
*Powered by Polymarket

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '25	$0.16	--	--	N/A
Q2 '25	$0.15	$0.16	9.09%	BEAT
Q1 '25	$0.10	$0.16	60.00%	BEAT
Q4 '24	-$0.04	$0.01	125.00%	BEAT
Q3 '24	$0.01	$0.10	566.67%	BEAT

AUPH
Aurinia Pharmaceuticals Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Upcoming Earnings: Q3 '25

Historical Earnings

Latest AUPH News

AUPHAurinia Pharmaceuticals Inc